Vivo Capital’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-294,909
Closed -$9.87M 50
2026
Q1
$9.87M Sell
294,909
-600,000
-67% -$23.5M 0.82% 31
2025
Q4
$41.4M Sell
894,909
-1,383,294
-61% -$75.8M 2.68% 12
2025
Q3
$154M Sell
2,278,203
-1,680,091
-42% -$125M 12.39% 1
2025
Q2
$332M Sell
3,958,294
-500,000
-11% -$37.4M 33.94% 1
2025
Q1
$319M Sell
4,458,294
-1,833,557
-29% -$89.3M 42.19% 1
2024
Q4
$283M Hold
6,291,851
31.68% 1
2024
Q3
$318M Sell
6,291,851
-1,025,000
-14% -$49.1M 26.29% 1
2024
Q2
$299M Sell
7,316,851
-1,101,242
-13% -$46.7M 27.58% 1
2024
Q1
$360M Hold
8,418,093
28.31% 1
2023
Q4
$339M Buy
8,418,093
+5,215,000
+163% +$148M 27.74% 1
2023
Q3
$94.5M Buy
+3,203,093
New +$19.4M 10.36% 2
2020
Q2
Sell
-134,758
Closed -$4.81M 57
2020
Q1
$4.81M Buy
+134,758
New +$5.73M 0.44% 41
2019
Q3
Sell
-284,597
Closed -$12M 26
2019
Q2
$12M Sell
284,597
-6,049
-2% -$209K 1.12% 24
2019
Q1
$8.98M Hold
290,646
0.9% 29
2018
Q4
$7.46M Hold
290,646
0.95% 27
2018
Q3
$9.42M Hold
290,646
0.95% 27
2018
Q2
$10.2M Buy
290,646
+21,744
+8% +$638K 1.31% 21
2018
Q1
$7.31M Hold
268,902
1.04% 20
2017
Q4
$7.26M Buy
268,902
+72,965
+37% +$2.1M 1.56% 17
2017
Q3
$7.64M Hold
195,937
1.54% 16
2017
Q2
$7.36M Hold
195,937
1.85% 12
2017
Q1
$10.4M Buy
195,937
+96,511
+97% +$5.69M 3.07% 9
2016
Q4
$6.04M Hold
99,426
1.99% 14
2016
Q3
$6.71M Hold
99,426
2.09% 13
2016
Q2
$8.65M Sell
99,426
-125
-0.1% -$11.4K 2.36% 10
2016
Q1
$8.88M Buy
+99,551
New +$9.75M 2.23% 13

Vivo Capital's SLNO Position: Q2 2026 in Review

Vivo Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 294,909 shares — an estimated $9.87M sold.

Vivo Capital first reported a position in SLNO in Q1 2016 and held it in 26 quarters. The position peaked at $360M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Vivo Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vivo Capital sold 294,909 Soleno Therapeutics shares in Q2 2026, an estimated $9.87M.
  • Vivo Capital first reported a position in Soleno Therapeutics in Q1 2016 and held it in 26 quarters.
  • Vivo Capital's Soleno Therapeutics position peaked at $360M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.